SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $46.00 to $47.88
• 50-Day Range: $34.63 to $59.93
• 52-Week Range: $28.21 to $62.00
• Volume: 1.33 million shs
• Average Volume: 1.30 million shs
• Market Capitalization: $3.55 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $73.20
• Consensus Rating: Buy

SpringWorks Therapeutics Stock Analysis - MarketRank™

SpringWorks Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 627th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SpringWorks Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($2.05) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SpringWorks Therapeutics is -13.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SpringWorks Therapeutics is -13.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SpringWorks Therapeutics has a P/B Ratio of 4.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.96% of the float of SpringWorks Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

SpringWorks Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SpringWorks Therapeutics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SpringWorks Therapeutics does not currently pay a dividend.

Dividend Growth

SpringWorks Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.96% of the float of SpringWorks Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

SpringWorks Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SpringWorks Therapeutics has recently increased by 5.91%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.38

News Sentiment

SpringWorks Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for SpringWorks Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for SWTX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.

MarketBeat Follows

8 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, SpringWorks Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,402,956.00 in company stock.

Percentage Held by Insiders

Only 7.61% of the stock of SpringWorks Therapeutics is held by insiders.

SWTX Stock Analysis - Frequently Asked Questions

How have SWTX shares performed this year?

SpringWorks Therapeutics' stock was trading at $36.13 at the beginning of 2025. Since then, SWTX shares have increased by 31.2% and is now trading at $47.41.
View the best growth stocks for 2025 here.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Thursday, February, 20th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.38. The company earned $61.55 million during the quarter, compared to analysts' expectations of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative trailing twelve-month return on equity of 46.74%.

Does SpringWorks Therapeutics have any subsidiaries?

SpringWorks Therapeutics subsidiaries include SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..

When did SpringWorks Therapeutics IPO?

SpringWorks Therapeutics (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (9.62%), Deep Track Capital LP (4.65%) and Boxer Capital Management LLC (4.60%). Insiders that own company stock include Orbimed Advisors Llc, Saqib Islam, Badreddin Edris, Daniel Lynch, Bhavesh Ashar, Daniel Pichl and Julie Hambleton.
View institutional ownership trends.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SpringWorks Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 2/20/2025
• Today: 3/28/2025
• Next Earnings (Estimated): 5/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SWTX
• CIK: 1773427
• Web: www.springworkstx.com
• Phone: 203-883-9490
• Fax: N/A
• Employees: 230
• Year Founded: 2017

Price Target and Rating

• Average Stock Price Target: $73.20
• High Stock Price Target: $81.00
• Low Stock Price Target: $65.00
• Potential Upside/Downside: +54.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($3.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-325,100,000.00
• Net Margins: -134.73%
• Pretax Margin: -203.09%
• Return on Equity: -46.74%
• Return on Assets: -41.12%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.16
• Quick Ratio: 6.02

Sales & Book Value

• Annual Sales: $191.59 million
• Price / Sales: 18.54
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.01 per share
• Price / Book: 4.74

Miscellaneous

• Outstanding Shares: 74,936,000
• Free Float: 68,725,000
• Market Cap: $3.55 billion
• Optionable: Optionable
• Beta: 0.76